98%
921
2 minutes
20
Introduction: Melanoma-associated retinopathy (MAR) is a distinct subset within the spectrum of retinal-dysfunction disorders. It is triggered by the cross-reaction between circulating antibodies originating from malignant melanoma (MM) and retinal antigens. The timely identification of paraneoplastic retinal diseases is crucial, as it can significantly contribute to the early diagnosis and treatment of underlying malignancies. Currently, increasing awareness of the early clinical manifestations of MAR is essential for clinicians to detect primary or metastatic MMs at an earlier stage.
Case Presentation: This report details a case of a patient who initially presented with night blindness and visual field defects as the primary symptoms. Through a comprehensive and systematic examination process, which involved detailed ophthalmological examinations and multidisciplinary diagnostic approaches, esophageal, and cardia MM was ultimately diagnosed. The patient was referred to an external hospital for comprehensive antitumor management, and posttreatment, the patient self-reported a notable improvement compared to the pretreatment state.
Conclusion: The purpose of sharing this case is to clarify the early clinical manifestations of MAR. It is anticipated that this will prompt clinicians to enhance their vigilance and identify primary or metastatic MMs earlier. Early treatment of the primary disease not only has the potential to reduce the risk of irreversible immune-mediated damage to retinal cells but also to improve visual outcomes. This highlights the significance of early diagnosis and intervention in the management of such diseases, providing important reference for clinicians.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12140611 | PMC |
http://dx.doi.org/10.1159/000545942 | DOI Listing |
Curr Opin Ophthalmol
August 2025
Massachussetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, USA.
Purpose Of Review: Autoimmune retinopathy (AIR) is a rare but vision-threatening disorder characterized by retinal damage through humoral or cellular immune mechanisms. The purpose of this review is to summarize our current understanding on imaging, antibody testing, and immunosuppressive therapies for AIR.
Recent Findings: AIR includes paraneoplastic forms - such as cancer-associated retinopathy (CAR) and melanoma-associated retinopathy (MAR) - as well as a nonparaneoplastic (np) variant (npAIR).
Int Ophthalmol
August 2025
Southampton Eye Unit, University Hospital Southampton, 103 Tremona Rd, Southampton, SO16 6HU, UK.
Purpose: To provide a comprehensive overview of the existing understanding regarding the clinical characteristics, diagnostic investigation, and treatment strategies for autoimmune retinopathy (AIR). To emphasize the lack of consensus in the field and the ongoing controversies regarding best practices.
Methods: Narrative review of the literature on PubMed and Google Scholar databases.
Respir Investig
September 2025
Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Atezolizumab in combination with chemotherapy is a standard treatment for extensive-stage small cell lung cancer (SCLC). However, it can induce immune-related adverse events and exacerbate autoimmune conditions. Cancer-associated retinopathy (CAR) is a known paraneoplastic syndrome in SCLC, but its interaction with immune checkpoint inhibitor (ICI) therapy remains poorly understood.
View Article and Find Full Text PDFOphthalmol Retina
August 2025
Department of Ophthalmology, Hamilton Eye Institute. University of Tennessee Health Science Center. Memphis, TN, USA. Electronic address:
Objective: Episcleral plaque brachytherapy (EPBT) provides effective local tumor control in uveal melanoma (UM), although dosing regimens vary across institutions. We report a single institution's experience of using low-dose rate Iodine-125 EPBT for the treatment of UM over a period of 38 years, evaluating long-term outcomes, complications, and survival rates.
Design: Retrospective chart review.
Eur J Neurol
August 2025
Department of Neurology, The First Affiliated Hospital of China Medical University, Shenyang, China.
Background: Myasthenia gravis (MG) is an autoimmune disorder affecting the neuromuscular junction (NMJ), driven by T cells, mediated by B cells, and dependent on autoantibodies. In addition to the typical motor symptoms of fluctuating weakness, the non-motor symptoms are also prevalent among MG patients. This review aims to present the non-motor symptoms of MG and their potential pathogenesis, hoping to contribute to personalized diagnosis and treatment.
View Article and Find Full Text PDF